On 25 April 2024, Evernorth, a provider of health services and member of the Cigna Group, announced that it will offer biosimilar adalimumab to US patients with no patient out-of-pocket costs from June 2024, resulting in savings to the patient of around US $3,500 per year . This biosimilar will be accessible to eligible patients through its specialty pharmacy, Accredo.
The first Humira® biosimilar [Amgen’s Amjevita], was launched in the US on 31 January 2023, with multiple additional biosimilars entering the US market in July 2023.